Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

[1]  B. Mellado,et al.  REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis. , 2015, Future oncology.

[2]  M. Fishman,et al.  Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Porta,et al.  Renal effects of targeted anticancer therapies , 2015, Nature Reviews Nephrology.

[4]  A. Ravaud,et al.  Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. , 2013, Cancer treatment reviews.

[5]  J. Dancey,et al.  Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Marschner,et al.  Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus , 2012, Clinical Cancer Research.

[7]  J. Machiels,et al.  An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. , 2012, European journal of cancer.

[8]  H. Akaza,et al.  Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. , 2011, European journal of cancer.

[9]  S. Sleijfer,et al.  Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. , 2011, Journal of the National Cancer Institute.

[10]  C. Szczylik,et al.  Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines , 2011, Kidney and Blood Pressure Research.

[11]  C. Porta,et al.  Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. , 2011, European journal of cancer.

[12]  H. Joensuu,et al.  Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma , 2011, Acta oncologica.

[13]  R. Figlin,et al.  Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib , 2011, Journal of the National Cancer Institute.

[14]  A. Ravaud.  Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. , 2011, The oncologist.

[15]  Hua Yu,et al.  Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers , 2010, Molecular Cancer Therapeutics.

[16]  B. Humphreys,et al.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. , 2010, Seminars in nephrology.

[17]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[18]  R. Motzer,et al.  Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Rini,et al.  Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). , 2008 .